VitroScans Chemo Sensitivity Score predicts response to carboplatin and paclitaxel for ovarian cancer patients

5 June 2023

First publication of the predictive value of our ex vivo tumor testing platform at ASCO23 by dr. Nelleke Ottevanger (Radboudumc) and dr. Judith Kroep (LUMC). A strong basis for the next step to implement our testing for treatment stratification for ovarian cancer patients. Join our clinical trial program by contacting us via support@vitroscan.nl.

Please click here to download the poster that was presented at ASCO23.